Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. - Wikidata - awgldk - TriplyDB

Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.

Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.

http://www.wikidata.org/entity/Q37957629

about

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?Current perspectives on cardiovascular outcome trials in diabetes Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes.Taking a low glycemic index multi-nutrient supplement as breakfast improves glycemic control in patients with type 2 diabetes mellitus: a randomized controlled trial.Update on Trial Registration 11 Years after the ICMJE Policy Was Established.Evaluation of a self-administered oral glucose tolerance test Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.

P2860

Q26740171-D02AFF85-9ED7-48C2-B150-E52A5C02394E Q26740247-3424F9FE-A6AC-4E63-B6EF-BEBAEC9ADBF0 Q28066006-03826C08-0E2F-4461-9E1B-71040252907B Q33698160-BAACD5AC-8D8F-4C5B-B674-245FE315B7DA Q34775039-A5A479E0-B626-4660-A4F8-C117753DB86C Q36259583-B188A465-CACE-4A78-A7D1-0F6E4317A90D Q36868182-F5A5764F-43D5-4F9B-8759-A97145F4AF6A Q38783203-913D9964-FB97-474D-B9F2-A608EB4FAD8F Q39228142-2A1FA400-1676-4DC4-9BFE-6DD223787E0C Q43092771-8FD43ABD-82B2-457D-86DB-3977ACB1E997 Q47113843-6EABE5B8-BA64-4EC9-B8D9-9D99221879F4

P2860

Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.

http://www.wikidata.org/entity/Q37957629

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Impact of FDA guidance for dev ...... sign: from policy to practice.

@en

Impact of FDA guidance for dev ...... sign: from policy to practice.

@nl

type

label

Impact of FDA guidance for dev ...... sign: from policy to practice.

@en

Impact of FDA guidance for dev ...... sign: from policy to practice.

@nl

prefLabel

Impact of FDA guidance for dev ...... sign: from policy to practice.

@en

Impact of FDA guidance for dev ...... sign: from policy to practice.

@nl

P1433

Q37957629-216BE4DD-CD21-4B6E-AAFB-EF0AC4E2A30A

P1476

Q37957629-577E1307-FBDE-4777-90B3-99D08648FD42

P2093

Q37957629-8832121E-B7DF-48BA-A165-CEC14EAA58D1

P2860

Q37957629-0AE48B01-1AC2-4EF7-890F-F2C754B22E2A

Q37957629-195FA8A4-B3B2-4568-93FC-E737FF13063F

Q37957629-294E3BC9-FC0F-4FE2-8206-94FF47C0D514

Q37957629-2D2B45DD-728E-4712-81E5-CEA4954B4D3B

Q37957629-2F783474-E0D2-40D3-B0FD-3B98B0ED9C80

Q37957629-390896EE-F5F5-4A99-848D-1906E222C42D

Q37957629-5F535C5E-8B06-4A35-84A2-59BDECFD3170

Q37957629-64ADF9AE-A5F7-4B66-AB40-4DF570A60294

Q37957629-66670C15-B90F-41A0-9205-22027F48266F

Q37957629-77F29CFF-E507-4044-ADC8-D5F264F5144C

P2888

Q37957629-3F12B676-B0AC-4D1E-87F8-E31D33EF93EE

P304

Q37957629-D2194756-67B0-40E1-A43A-1C2FDC1504BD

P31

Q37957629-99BE5549-66B9-437D-B561-998D7FEB01D3

P356

Q37957629-6AA04E10-77E2-4FEC-8163-C9EE5CECB7DD

P433

Q37957629-43B6BCCB-9267-4EB0-8A96-0B66B6365595

P478

Q37957629-2394381F-5BF4-42FB-A3EB-30B269C52518

P50

Q37957629-C985DD12-BA01-427D-BE8F-4D572C9D3700

P577

Q37957629-32250167-5F9A-4DE3-9F44-CA8EED58A612

P698

Q37957629-9FC0474C-37DD-48F4-AE02-850AAC178AE9

P356

S11886-011-0229-7

P1433

Current cardiology reports

P1476

Impact of FDA guidance for dev ...... esign: from policy to practice

@en

P2093

Harald Sourij

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

The importance of independent academic statistical analysis.

The ClinicalTrials.gov results database--update and key issues

Diabetes mellitus, fasting glucose, and risk of cause-specific death.

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Therapeutic roles of peroxisome proliferator-activated receptor agonists.

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

P2888

s11886-011-0229-7

P304

59-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-011-0229-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Mary Angelyn Bethel

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22094711

http://www.w3.org/2001/XMLSchema#string